Hyperthermia continues to show clinical benefits in randomized trials across a spectrum of malignancies, with generally well-tolerated side effects when administered as multimodality therapy.

Hyperthermia contributes direct tumor cell killing and may also enhance the antitumor effects of chemotherapy and radiation therapy.

Its widespread adoption has been impeded by technological and delivery barriers that are now being addressed through new commercial solutions.

It would serve physicians of all on cological disciplines to stay informed of new developments and consider integrating these promising techniques into their practice.